BNP/PUT/ELI LILLY & CO/700/0.1/21.03.25 | Market Closed - Boerse Frankfurt Warrants 15:50:30 2024-07-03 EDT | ||
| 2.04 EUR | +6.81% |
|
| Current month | +13.89% | ||
| 1 month | -32.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 2.05 | +7.33% |
| 24-07-02 | 1.91 | +9.14% |
| 24-07-01 | 1.75 | -2.78% |
| 24-06-28 | 1.8 | -1.10% |
| 24-06-27 | 1.82 | -7.14% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 03:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC9XJA |
| ISIN | DE000PC9XJA2 |
| Date issued | 2024-05-15 |
| Strike | 700 $ |
| Maturity | 2025-03-21 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 3.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.63 € |
|---|---|
| Lowest since issue | 1.7 € |
| Spread | 0.11 € |
| Spread % | 5.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
